Diabetes
-
Permission granted by Dexcom
Dexcom to add 2 board directors with activist investor Elliott
CEO Jake Leach also discussed the company’s plans for its G8 glucose sensor, dual-analyte sensing and Medicare coverage at an investor day.
By Elise Reuter • May 15, 2026 -
Courtesy of Tandem Diabetes Care
Tandem to file tubeless insulin pump with FDA this quarter
The new version of Tandem’s Mobi pump would be the diabetes technology company’s first tubeless device.
By Elise Reuter • May 8, 2026 -
Explore the Trendlineâž”
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Courtesy of Insulet Corp.
Insulet raises revenue expectations for 2026
CEO Ashley McEvoy also shared an update on the company’s recent recall of insulin patch pumps.
By Elise Reuter • May 6, 2026 -
Courtesy of Insulet
Insulet starts study of closed loop insulin delivery system
Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.
By Elise Reuter • May 4, 2026 -
Courtesy of Trividia Health
FDA advises users of Trividia glucometer to switch to alternatives
The potential for error code confusion to cause delayed or improper treatment led the FDA to recommend users transition to other blood glucose meters.
By Nick Paul Taylor • April 30, 2026 -
Courtesy of Tandem Diabetes Care
Tandem recalls Mobi insulin pumps over software malfunction
A malfunction may cause insulin delivery to stop. Tandem instructed users to update their pump software as soon as possible.
By Elise Reuter • April 22, 2026 -
Courtesy of MiniMed
MiniMed posts double-digit sales growth, widening net loss
New glucose sensors and a partnership with Abbott are expected to drive sales growth at MiniMed, BTIG analyst Marie Thibault wrote.
By Elise Reuter • April 21, 2026 -
Permission granted by Glucotrack
Glucotrack plans US trial of implantable glucose monitor this year
Glucotrack plans to file for an investigational device exemption in the second quarter, with hopes of starting a trial in the second half of 2026.
By Elise Reuter • March 27, 2026 -
Courtesy of MiniMed
Medtronic lowers earnings forecast after MiniMed IPO
The timing of the initial public offering and the clearance of a new insulin pump are expected to affect Medtronic’s results for its 2026 fiscal year.
By Elise Reuter • March 25, 2026 -
Retrieved from Owen Mumford on March 19, 2026
Embecta to buy Owen Mumford for up to $201M
The planned purchase would allow Embecta to serve patients outside of diabetes care.
By Elise Reuter • March 19, 2026 -
Courtesy of MiniMed
MiniMed gets FDA nod for smaller insulin pump
MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed’s previous device. It’s the company’s first launch since separating from Medtronic in early March.
By Elise Reuter • March 18, 2026 -
Courtesy of Insulet Corp.
Insulet reports 18 serious adverse events with recall of Omnipod 5 insulin pumps
The company is recalling certain lots of its insulin patch pumps after finding a small tear in the internal tubing may cause insulin to leak inside the pod.
By Elise Reuter • March 13, 2026 -
Permission granted by Insulet
Insulet posts clinical data on fully closed-loop insulin delivery system
The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
By Nick Paul Taylor • March 12, 2026 -
Permission granted by Medtronic
Medtronic’s MiniMed goes public for $560M
The diabetes tech business is now operating as a standalone, public company. Shares began trading on Friday.
By Elise Reuter • March 6, 2026 -
Sarah Silbiger via Getty Images
FDA warns insulin infusion set maker Unomedical over leaks, mishandled complaints
Unomedical, which supplies diabetes tech firms including Medtronic, Tandem Diabetes Care and Beta Bionics, received more than 5,000 complaints about leaking infusion sets between 2023 and 2025.
By Elise Reuter • March 2, 2026 -
Courtesy of Beta Bionics
FDA warns Beta Bionics on unreported complaints, insulin pump changes
The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings.
By Elise Reuter • Feb. 26, 2026 -
Permission granted by Dexcom
AdvaMed names Jake Leach as chair of diabetes sector
The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.
By Elise Reuter • Feb. 24, 2026 -
Permission granted by Medtronic
Medtronic’s MiniMed prices IPO at up to $784M
The diabetes spinoff plans to offer 28 million shares at $25 to $28 each.
By Elise Reuter • Feb. 24, 2026 -
Courtesy of Medtronic
Medtronic to cut 81 employees at California diabetes site
As Medtronic prepares to spin out its diabetes business, a spokesperson said the company is considering the structure, capabilities and scale needed to succeed.
By Elise Reuter • Feb. 20, 2026 -
Permission granted by Senseonics
Senseonics launches automated insulin dosing system with 1-year CGM
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
By Nick Paul Taylor • Feb. 20, 2026 -
Permission granted by Dexcom
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
By Elise Reuter • Feb. 13, 2026 -
Courtesy of Medtronic
Medtronic wins expanded FDA label for 780G insulin pump
The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.
By Nick Paul Taylor • Feb. 5, 2026 -
Permission granted by Abbott Laboratories
Abbott receives FDA warning letter over Freestyle Libre CGMs
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
By Elise Reuter • Feb. 3, 2026 -
Courtesy of Beta Bionics
Beta Bionics receives FDA warning letter
The letter, which the FDA has not yet published, does not affect Beta Bionics’ ability to market, manufacture or distribute products, the company said.
By Elise Reuter • Feb. 2, 2026 -
Permission granted by Senseonics
Senseonics wins CE mark for one-year CGM
The company is hiring sales reps and transitioning staff from its former partner to support launches in Germany, Italy, Spain and Sweden.
By Nick Paul Taylor • Jan. 30, 2026
